The Clinical Effect of Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis: Single Arm Open-label Trial
Latest Information Update: 13 Oct 2025
At a glance
- Drugs Levofloxacin (Primary)
- Indications Cutaneous leishmaniasis
- Focus Therapeutic Use
Most Recent Events
- 30 Sep 2025 Planned End Date changed from 1 May 2025 to 1 Nov 2025.
- 30 Sep 2025 Planned primary completion date changed from 1 May 2025 to 1 Nov 2025.
- 04 Feb 2025 New trial record